SNGX
$1.68
Soligenix
($.02)
(1.32%)
SNGX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.10)
Revenue:  $1.10 Mil
Tuesday
Nov 10
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SNGX reports earnings?
Beat
Meet
Miss

Where is SNGX's stock price going from here?
Up
Flat
Down
Stock chart of SNGX
Analysts
Summary of analysts' recommendations for SNGX
Score
Grade
Pivots
Resistance
$1.83
$1.79
$1.74

$1.70

Support
$1.65
$1.61
$1.56
Tweet
Growth
Description
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerEli Lilly